| Aug 21 |
Regeneron confirms FDA won’t approve myeloma drug over manufacturing issues
|
| Aug 21 |
Biotech Stock Roundup: CRL for REGN, GILD's Drug Approval, LQDA Down on News
|
| Aug 21 |
Regeneron (REGN) Gets CRL From FDA for Multiple Myeloma Drug
|
| Aug 21 |
Regeneron receives anticipated FDA rejection for blood cancer therapy
|
| Aug 21 |
Regeneron Faces Setback With FDA Rejection Of Blood-Cancer Treatment
|
| Aug 20 |
Regeneron Provides Update on Biologics License Application for Linvoseltamab
|
| Aug 20 |
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $130 Thousand Today
|
| Aug 17 |
Regeneron Pharmaceuticals' (NASDAQ:REGN) five-year earnings growth trails the incredible shareholder returns
|
| Aug 15 |
Alvotech’s biosimilar to Regeneron’s Eylea under EU review
|
| Aug 13 |
7 Stocks That Usually Benefit From a Recession
|
